Your Yourlocation: Home > Treatment of chronic obstructive pulmonary disease with tiotropium bromide(136310-93-5) and formoterol inhalation

Tiotropium bromide(136310-93-5) is a new inhaled bronchodilator, a first-line treatment for chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate the efficacy and safety of tiotropium combined with formoterol in COPD patients.

Materials and Methods:

Source: selected in our hospital respiratory medicine in patients with COPD in 46 cases, all cases meet the Chinese Medical Association respiratory disease branch will develop diagnostic criteria. (67.5 ± 6.8) years. In the control group, 23 patients (15 males and 8 females, mean (66.9 ± 6.2) years were randomly divided into two groups: the treatment group (23 males, 16 males and 7 females). There was no significant difference in the disease, sex and age between the two groups (P> 0.05). Excluding the merger of other cardiopulmonary disease.

Treatment: The two groups using the same conventional treatment, including control of infection, phlegm, oxygen, etc., during the treatment without glucocorticoid, not inhaled other anticholinergic drugs and long-acting β2 agonists. In the treatment group, tiotropium bromide(136310-93-5) powder was inhaled at a dose of 18μg /d, inhaled formoterol 9μg once daily. The control group inhaled formoterol 9μg, 1 times /d, both groups continued treatment for 4 weeks.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved